Atherosclerotic cardiovascular diseases are the clinical outcome of a process combining prolonged exposures, arterial wall changes, and ischemic or thrombotic complications. Atherosclerosis describes the structural disease of the arteries; risk factors describe conditions that promote its onset, progression, or clinical events. Effective prevention requires addressing both levels: reducing exposures before they cause damage and recognizing disease that is already present, even before symptoms have developed.
Their impact extends beyond ischemic heart disease. Coronary, carotid, aortic, peripheral, and visceral plaques may share biological determinants while producing very different clinical presentations. Myocardial infarction, some strokes, limb ischemia, and certain forms of intestinal ischemia are manifestations of this systemic process. Diabetes, obesity, hypertension, and kidney disease may also cause heart failure and other complications through pathways that are not exclusively atherosclerotic. Therefore, cardiovascular risk must be interpreted by specifying which events are being predicted and over what time horizon.
The Global Burden of Disease 2019 estimated 523 million people living with cardiovascular disease and 18.6 million cardiovascular deaths in 2019. These figures include conditions other than atherosclerosis and do not directly measure its prevalence. Arterial wall disease is much more common than its clinical manifestations: a substantial proportion of lesions remain silent for years, while aging and duration of exposure increase disease burden. The interval between biological onset and the first event presents an opportunity for prevention, but makes a strategy that invariably waits for pain or loss of function inadequate.
The central causal event in atherogenesis is the entry and retention in the intima of lipoprotein particles containing apoB. The cholesterol they carry contributes to extracellular and intracellular deposits, while the arterial wall responds with endothelial activation, immune-cell recruitment, and matrix production. Over time, plaques form that may contain fibrous, lipid-rich, or calcific components in varying proportions. The likelihood of this process becoming clinically significant also depends on duration: an unfavorable concentration maintained over decades represents a different exposure from the same value that has only recently appeared.
Dyslipidemias encompass heterogeneous abnormalities and cannot be described simply as “high cholesterol.” Hypercholesterolemia mainly concerns exposure to LDL; elevated triglycerides may accompany an excess of triglyceride-rich lipoproteins and remnants; and several abnormalities coexist in mixed dyslipidemia. LDL-C, non-HDL-C, and apoB concentrations describe related but distinct aspects of the same circulating lipoprotein population. The most useful parameter depends on the clinical question and any discordance between cholesterol mass and particle number.
Inherited predisposition can bring the natural history forward substantially. In familial hypercholesterolemia, the LDL burden is increased from the earliest stages of life and calls for early recognition, including assessment of relatives. Lp(a) is another largely genetically determined factor that cannot be identified from total cholesterol alone. However, a suggestive family history does not amount to a genetic diagnosis: it must be reconstructed carefully, noting the type of event, age, and degree of relatedness, and distinguishing monogenic disorders from polygenic or environmental clustering.
Elevated blood pressure and smoking affect both lesion development and the potential for complications. Blood pressure changes the mechanical load on the arterial wall; smoking impairs endothelial function and promotes an oxidative, prothrombotic environment. The contribution of one condition should not be considered in isolation: combined exposures may amplify risk even when each measurement appears only moderately abnormal. Conversely, correcting a single determinant does not necessarily eliminate risk from others or from damage already accumulated.
Inflammation links lipid retention to plaque progression. Cholesterol-laden macrophages, cell death, impaired clearance of debris, and smooth muscle cell activity alter lesion structure. A robust fibrous cap can keep blood separate from thrombogenic material; rupture of the cap or loss of the endothelial lining may promote thrombosis. Stenosis and the propensity for thrombosis are not identical properties: a minimally obstructive plaque may contribute to an acute event, whereas chronic stenosis may mainly limit blood flow during exertion. This explains why prevention requires systemic treatment in addition to any intervention on an individual lesion.
Metabolic conditions affect the arterial tree through multiple pathways. Insulin resistance promotes increased fatty acid availability, hepatic lipoprotein production, and altered distribution of body fat. Metabolic syndrome identifies a cluster of abnormalities but does not replace the diagnosis and treatment of each component. Two people with the same label may have different atherogenic burdens and prognoses; assessment must therefore pay specific attention to blood pressure, lipids, glycemia, and adiposity.
The relationship between obesity and cardiovascular risk does not depend exclusively on total body weight. Visceral fat distribution, adipose tissue function, physical activity, duration of excess weight, and comorbidities contribute to individual variability. Adiposity may promote hypertension, lipid abnormalities, and diabetes, but also affects hemodynamics and cardiac function. Assessment based on body mass index alone misses some of this complexity, while the current absence of metabolic abnormalities does not guarantee lasting protection.
In diabetes, risk depends on disease duration, target-organ damage, kidney function, and coexisting factors. Hyperglycemia and glycation contribute to injury, but cardiovascular management involves more than lowering HbA1c. Differences in benefits among glucose-lowering drugs demonstrate that glycemic outcomes, protection against atherothrombosis, prevention of heart failure, and kidney protection are related but distinct goals. Neuropathy may also alter the perception of ischemic symptoms and make advanced disease less apparent.
Chronic kidney disease is a setting in which endothelial dysfunction, hypertension, inflammation, and metabolic abnormalities overlap. eGFR and albuminuria must be considered together because they describe different dimensions of damage. In advanced stages, vascular calcification, heart failure risk, and treatment complexity also increase, including challenges in selecting antithrombotic therapy. Medial calcification, which is particularly common in this setting, must be distinguished from intimal plaque to avoid confusing arterial stiffness with atherosclerotic stenosis.
Among other determinants, obstructive sleep apnea may be associated with intermittent hypoxia, sympathetic activation, and difficulty controlling blood pressure. Treatment follows specific respiratory and clinical indications; improvement in an intermediate parameter must not automatically be presented as proof that all cardiovascular events are prevented. Inflammatory diseases, particulate matter exposure, social conditions, and prolonged stress complete the picture. The strength of causal evidence and availability of effective interventions vary among determinants: recognizing this difference is part of scientific accuracy, not a reason to disregard them.
Most risk factors and early plaques do not produce a specific symptom. History-taking therefore reconstructs exposures and clinical history even before investigating a particular syndrome. Previous lipid results, duration of smoking, blood pressure trends, metabolic history, family events, and treatments already taken help explain what an isolated test cannot reveal. Any previous clinical disease must be established from documentation, because it profoundly changes the protection required and the interpretation of preventive risk scores.
When symptoms appear, their location and sequence guide the evaluation. Chest pressure or exertional dyspnea may suggest myocardial ischemia; focal disturbances of speech, strength, or vision require cerebrovascular assessment; muscle pain on walking and foot lesions raise the possibility of peripheral artery disease. History-taking must clarify onset, duration, triggers, and course. A sudden change is not simply a shift in future risk: it may indicate an ongoing complication requiring urgent investigation.
Physical examination follows this history. Properly measured blood pressure, heart rate and rhythm, body weight, and adiposity distribution provide baseline data. Cardiopulmonary auscultation, comparison of peripheral pulses, neurological assessment, and limb inspection look for consequences or signs of disease. Tendon xanthomas may support suspicion of an inherited disorder; ulcers, temperature changes, and diminished pulses suggest peripheral vascular impairment. The absence of findings does not exclude plaque, and a bruit alone does not quantify its severity.
The clinical consultation must also integrate functional capacity, frailty, and the ability to follow treatment. A person may report few symptoms because they have gradually reduced activities, or stop medication because of adverse effects or practical difficulties. This information influences prognosis as much as a correctly measured laboratory value. The relationship between risk and disease must therefore be explained without conflating the two concepts: a person may have high risk without a clinical event, silent plaque with varying risk, or established disease requiring secondary prevention.
There are no single diagnostic criteria for the overall category of “atherosclerosis and risk factors”: each condition requires a specific approach. Blood pressure must be confirmed with appropriate measurements; glycemic abnormalities must be interpreted according to accepted criteria for diabetes and intermediate states; dyslipidemias require lipid profile characterization and investigation of secondary causes. The diagnosis of a plaque, by contrast, requires an anatomical investigation appropriate to the arterial territory. A prognostic risk score cannot replace any of these steps.
Initial laboratory assessment generally includes a lipid profile, glycemic assessment, and kidney function, with further tests according to history and findings. Non-HDL-C and apoB may clarify lipoprotein burden when LDL-C is insufficient; Lp(a) can reveal an otherwise unrecognized inherited component. Drugs, hypothyroidism, kidney or liver diseases, and other conditions can alter lipid levels, so dyslipidemia must be interpreted beyond comparison with the laboratory reference range. Markedly elevated triglycerides also raise the distinct concern of pancreatitis, beyond atherosclerotic risk alone.
In people without known disease, the European SCORE2 and SCORE2-OP algorithms allow risk estimation for their respective age ranges and the appropriate calibration region. Diabetes requires specific tools and classifications. Clinical cardiovascular disease, important inherited disorders, and target-organ damage may make use of a general-population calculator inappropriate. The risk category must be linked to the document being applied, because thresholds for general prevention and those adopted in the 2025 ESC/EAS lipid update are not automatically equivalent. The percentage is a decision-support tool, not a standalone label.
Imaging is chosen according to the clinical question. Duplex Doppler ultrasound and peripheral blood pressure measurements are useful when peripheral artery disease is suspected; coronary CT and functional tests address different questions in patients with suspected ischemia; CT and MRI characterize other vascular territories when indicated. When preventive decisions are uncertain, coronary artery calcium or detection of peripheral plaques may refine assessment in selected individuals. Not every person with a risk factor needs all their arteries examined. Investigation for target-organ damage and polyvascular involvement should yield information useful for management.
Prevention combines lifestyle interventions, drug therapies, and, when there is disease with a specific indication, revascularization procedures. The objective is to reduce overall exposure and clinical events, not merely normalize one parameter. Smoking cessation requires active support, while diet, physical activity, and adiposity management must be adapted to clinical conditions and real-world possibilities. A strategy sustained over time provides greater benefit than very ambitious recommendations that are quickly abandoned.
Lowering LDL-C plays a central role because it targets an established cause. Statins, ezetimibe, and additional drugs are selected according to the baseline level, the reduction needed, tolerability, and evidence on clinical outcomes. Treatment intensity increases with risk; in clinical ASCVD, lipid-related prevention is generally much more intensive than in someone without disease who is at low risk. Familial forms and specific abnormalities require further decisions. Reducing a biomarker and reducing clinical events are distinct outcomes, particularly when evaluating innovative treatments.
Blood pressure and diabetes must be treated with goals consistent with the overall clinical picture. Therapy for a patient with diabetes and heart failure may differ from that for a patient whose main concern is atherothrombotic risk; kidney function guides treatment selection and safety. Obesity merits its own management program, which may include medications or surgery when indicated. Antiplatelet agents have an established role in many secondary prevention settings, but are not an automatic consequence of elevated cholesterol or a high risk score. Bleeding risk is part of assessing net benefit.
Revascularization can restore impaired blood flow and improve symptoms or prognosis in appropriate settings, but does not replace systemic prevention. Even after a successful procedure, exposures and other potentially important plaques remain. Follow-up checks response, adherence, adverse effects, and clinical changes. Prognosis is influenced by age, disease extent, previous events, organ function, and treatment continuity; it does not depend on stenosis percentage alone. Intervention before substantial damage accumulates may confer a lifetime advantage that short-term risk only partially reflects.
The most important atherosclerotic complications include myocardial infarction, ischemic stroke, and peripheral ischemia caused by thrombosis, embolization, or inadequate perfusion. Organ damage may leave scarring, reduced function, and permanent disability. Heart failure and arrhythmias may develop after myocardial infarction; motor, cognitive, and swallowing deficits may persist after stroke; and ulcers, infection, and necrosis in an ischemic limb can lead to amputation. The same systemic disease thus has different consequences depending on the affected territory and timeliness of treatment.
Associated conditions may produce additional outcomes. Diabetes and kidney disease mutually increase risk and make management more complex; hypertension also contributes to cardiac, renal, and cerebrovascular damage that is not entirely mediated by plaques. Very severe dyslipidemias may have specific manifestations, such as pancreatitis in marked hypertriglyceridemia, which should not be called complications of atherosclerosis. Distinguishing different mechanisms allows appropriate investigations and treatments to be selected instead of attributing every cardiovascular problem to a single cause.
Disease affecting multiple territories and recurrence after a first event identify people with a particularly high need for protection. At the same time, bleeding, adverse effects, and procedural complications may limit the intensity of some treatments. Outcomes depend on balancing event prevention, safety, and preservation of independence. An integrated approach connects lipid abnormalities, metabolic conditions, and other determinants to the patient's clinical history without reducing this complexity to a single test or prognostic category.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.